Boehringer Ingelheim Rcv Boehringer Ingelheim competitive analysis

Latest publications and patents of Boehringer Ingelheim Rcv Boehringer Ingelheim New

Explore the latest publications and patents granted to Boehringer Ingelheim Rcv Boehringer Ingelheim, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Boehringer Ingelheim Rcv Boehringer Ingelheim against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAMar 22, 2022
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERNov 16, 2021
Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation StatusIRMDec 15, 2020
Anti-B7-H6 Antibody, Fusion Proteins, And Methods Of Using The SameTRUSTEES OF DARTMOUTH COLLEGEDec 20, 2019
Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAJun 12, 2019
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAJan 2, 2019
Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)NOVARTISSep 25, 2018

Latest PTAB cases involving Boehringer Ingelheim Rcv Boehringer Ingelheim

Discover the latest PTAB cases involving Boehringer Ingelheim Rcv Boehringer Ingelheim, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Boehringer Ingelheim Rcv Boehringer Ingelheim with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
BOEHRINGER INGELHEIM RCV BOEHRINGER INGELHEIM7 - - - Highly Aggressive
CHUGAI SEIYAKU KABUSHIKI KAISHA376 - 1Defensive
NOVARTIS6406 - 21Defensive
THE UNIVERSITY OF TOKYO - 16 - 1Non-Active